PD-L1 inhibitors can specifically bind to PD-L1 on tumor cells to inhibit its expression, thereby enabling T cells, whose function has been suppressed, to restore their ability to recognize tumor cells.

Ractigen Therapeutics, a pioneer in saRNA therapy, has submitted an Australian clinical trial application to commence a Phase I trial.

Soft drugs are pharmaceuticals that are easily metabolized and inactivated.

Century Therapeutics, a leader in iPSC-derived cell therapies for cancer and autoimmune diseases, announced FDA approval for their Phase 1 trial evaluating CNTY-101 in moderately to severely affected lupus patients unresponsive to at least two standard immunosuppressants.

NTRK fusion is a driving factor in various adult and pediatric cancers, especially in certain rare tumors like infantile fibrosarcoma and secretory breast cancer, where it is highly enriched. Therefore, the future application prospects of NTRK inhibitors in this area are very promising.

Cocrystal Pharma has initiated the enrollment of the first participant in a Phase 2a clinical trial aimed at assessing the efficacy of the orally-administered CC-42344 for both pandemic and seasonal influenza A strains.

Protein drugs, also known as biologics, have revolutionized the treatment of various diseases by specifically targeting specific molecules or pathways involved in disease progression.

The Phase 3 study for Sarclisa® (isatuximab) delays disease progression in newly diagnosed multiple myeloma patients who are unsuitable for stem cell transplantation.

PARP1 inhibitors are a class of drugs that target the PARP1 enzyme, crucial for DNA repair, and are particularly effective against certain cancers.

Wave Life Sciences has launched the first stage of treatment in its RestorAATion study, which assesses the pioneering RNA editing treatment, WVE-006, aimed at combatting Alpha-1 Antitrypsin Deficiency.

Active targeting of a drug is typically achieved by conjugating it to a target entity that improves bioavailability and reduces systemic toxicity.

CatalYm Reports Promising Results for Phase 2a Trial with Visugromab Treating Late-Stage NSCLC and Bladder Cancer During the 2023 ESMO Immuno-Oncology Meeting.